最近，精准医学使得生物标志物驱动的治疗能够在泛肿瘤环境中进行，即所谓的组织不可知疗法。这代表了癌症护理从传统的特定癌症类型到以生物标志物为中心的护理的范式转变，其中根据跨癌症类型发生的分子畸变来选择患者进行此类治疗，而不管肿瘤部位或组织学如何。这种方法特别重要，因为它为患有罕见癌症或没有足够治疗方法的患者提供了新的治疗选择。因此，以组织不可知论为目标的药物开发可以加速药物审批并解决未满足的医疗需求。在此，我们讨论了我们对组织不可知治疗的特征的看法，并根据这些特征提出了早期药物发现的策略。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

Recently, precision medicine has enabled biomarker-driven treatment to be administered in a pan-tumor setting, so-called tissue-agnostic therapy. This represents a paradigm shift in cancer care from conventional cancer type-specific to biomarker-centric care, where patients are selected for this type of therapy based on molecular aberrations that occur across cancer types, regardless of tumor site or histology. This approach is particularly important because it offers new treatment options for patients with rare cancers or for whom there are no adequate treatments. Therefore drug development with the goal of tissue agnosticism can accelerate drug approval and address unmet medical needs. Herein, we discuss our opinions on the hallmarks of tissue-agnostic treatments and propose strategies for early drug discovery based on these hallmarks.Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.